Stock Events

Stock Events

Anixa Biosciences 

$2.79
64
+$0.04+1.45% Friday 20:00

Statistics

Day High
2.82
Day Low
2.76
52W High
5.22
52W Low
2.5
Volume
40,500
Avg. Volume
-
Mkt Cap
93.12M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5JunExpected
Q2 2024
Q4 2024
Q4 2024
Q1 2025
Q2 2025
Q4 2025
Next
-0.1
-0.09
-0.08
-0.08
Expected EPS
-0.085
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-21.85MNet Income

Analyst Ratings

10Average Price Target
The highest estimate is 10.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ANIX. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap166.82B
Gilead Sciences is a biopharmaceutical company that develops and markets drugs in areas similar to Anixa, including oncology, making it a direct competitor.
Merck
MRK
Mkt Cap302.33B
Merck & Co., Inc. is a global healthcare company that produces cancer treatments and vaccines, competing in the oncology and immunotherapy spaces like Anixa.
Bristol-Myers Squibb
BMY
Mkt Cap121.42B
Bristol-Myers Squibb operates in the biopharmaceutical field focusing on cancer, a key area for Anixa, making them competitors in developing treatments for various cancers.
AMGEN
AMGN
Mkt Cap183.12B
Amgen is a biotech company focusing on human therapeutics, including oncology and inflammation, areas where Anixa is also aiming to make significant contributions.
Pfizer
PFE
Mkt Cap147.62B
Pfizer is involved in the discovery, development, and manufacture of healthcare products including cancer treatments, directly competing with Anixa's focus areas.
Novartis
NVS
Mkt Cap290.05B
Novartis AG focuses on patented medicines for a range of diseases, including cancer, directly competing with Anixa in the oncology research and development space.
Roche
RHHBY
Mkt Cap343.56B
Roche Holding AG is a major player in pharmaceuticals and diagnostics with a strong focus on oncology, making it a competitor to Anixa in cancer research and treatment.
Astrazeneca
AZN
Mkt Cap290.06B
AstraZeneca PLC is a biopharmaceutical company focusing on the discovery, development, and commercialization of prescription medicines, including for cancer, competing with Anixa.
Johnson & Johnson
JNJ
Mkt Cap564.11B
Johnson & Johnson engages in the research and development, manufacture, and sale of a broad range of healthcare products, including cancer treatments, competing with Anixa.
Regeneron Pharmaceuticals
REGN
Mkt Cap66.98B
Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for treating serious medical conditions, including cancer, similar to Anixa's focus.

About

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
Show more...
CEO
Dr. Amit Kumar Ph.D.
Employees
5
Country
United States
ISIN
US03528H1095

Listings

STU
DE
CY71.STU
MU
DE
CY71.MU
XNAS
US
ANIX
F
DE
CY71.F

0 Comments

Share your thoughts

FAQ

What is Anixa Biosciences stock price today?▼
The current price of ANIX is $2.79 USD — it has increased by +1.45% in the past 24 hours. Watch Anixa Biosciences stock price performance more closely on the chart.
What is Anixa Biosciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Anixa Biosciences stocks are traded under the ticker ANIX.
Is Anixa Biosciences stock price growing?▼
ANIX stock has risen by +4.49% compared to the previous week, the month change is a -8.52% fall, over the last year Anixa Biosciences has showed a +11.6% increase.
What is Anixa Biosciences market cap?▼
Today Anixa Biosciences has the market capitalization of 93.12M
When is the next Anixa Biosciences earnings date?▼
Anixa Biosciences is going to release the next earnings report on June 05, 2026.
What were Anixa Biosciences earnings last quarter?▼
ANIX earnings for the last quarter are -0.08 USD per share, whereas the estimation was -0.09 USD resulting in a +10.16% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Anixa Biosciences revenue for the last year?▼
Anixa Biosciences revenue for the last year amounts to 0 USD.
What is Anixa Biosciences net income for the last year?▼
ANIX net income for the last year is -21.85M USD.
How many employees does Anixa Biosciences have?▼
As of May 26, 2026, the company has 5 employees.
In which sector is Anixa Biosciences located?▼
Anixa Biosciences operates in the Health & Wellness sector.
When did Anixa Biosciences complete a stock split?▼
The last stock split for Anixa Biosciences was on June 26, 2015 with a ratio of 1:25.
Where is Anixa Biosciences headquartered?▼
Anixa Biosciences is headquartered in San Jose, United States.